Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Next Previous
X
Search
Trial Profile

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolinapant (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Carcinoma; Cervical cancer; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Head and neck cancer; Lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Astex Pharmaceuticals; Taiho Oncology

    • Most Recent Events

    • 04 Dec 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2025.
    • 03 Aug 2023 Planned End Date changed from 1 May 2023 to 1 Oct 2024.
    • 03 Aug 2023 Planned primary completion date changed from 1 May 2023 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top